InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Tuesday, 04/30/2019 4:50:35 PM

Tuesday, April 30, 2019 4:50:35 PM

Post# of 2104
News: $CNAT Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication 1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats...

Find out more https://marketwirenews.com/news-releases/conatus-pharmaceuticals-announces-publication-demonstrating-that-emricasan-ameliorates-portal-hypertension-improves-liver-structure-and-function-in-a-preclinical-model-of-advanced-cirrhosis-8082678.html